We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

YEXT:NYSEYext, Inc. Analysis

Data as of 2026-05-28 - not real-time

$3.94

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Yext trades around $3.94, just above its recent support level and well below its 52‑week high, while the 20‑day SMA sits below the current price, indicating modest short‑term momentum. The 14‑day RSI hovers near the neutral zone and the MACD histogram is positive, suggesting a slight bullish tilt despite an overall bearish trend direction. Valuation metrics are mixed: the trailing P/E of 56x far exceeds the industry average, and the DCF‑derived fair value of roughly $3.47 is under the market price, pointing to a potentially overvalued stock in the near term. However, forward earnings estimates imply a much lower forward P/E of about 5.6, and analyst price targets have been adjusted to a $6‑$8 range, leaving substantial upside potential. Fundamentally, revenue is flat year‑over‑year and operating margins are negative, yet gross margins remain strong at 75% and free cash flow is positive. The company’s cash balance exceeds its debt, but the debt‑to‑equity ratio is high, reflecting leverage concerns. Recent news highlights a split analyst view, with bullish commentary focusing on cost discipline and early traction for the Scout product, while bearish notes raise questions about sub‑par fundamentals and a possible management buyout. Volatility is elevated at nearly 47% over the past month, and trading volume has been on a downtrend, adding liquidity risk.
Given the blend of technical softness, overvalued current pricing, and a forward‑looking earnings recovery narrative, Yext appears positioned for a cautious approach. Investors should weigh the upside implied by analyst targets against the high valuation multiples and operational challenges, while monitoring volume trends and any developments around the rumored buyout. The stock’s risk profile is heightened by its sector’s medium‑level exposure and the company’s uncertain growth trajectory, suggesting a balanced hold with selective upside bias.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish technical trend despite slight MACD bullish signal
  • Current price above support but below resistance
  • High valuation multiples relative to peers

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Forward earnings estimate implies low forward P/E
  • Analyst target range of $6‑$8 suggests upside
  • Cost discipline and early traction of Scout product

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Uncertainty around potential management buyout
  • Sustained negative operating margin and modest revenue growth
  • Strong gross margin and positive free cash flow provide a floor

Key Metrics & Analysis

Financial Health

Revenue Growth-1.00%
Profit Margin8.48%
P/E Ratio56.3
ROE24.23%
ROA-0.09%
Debt/Equity111.94
P/B Ratio3.0
Op. Cash Flow$55.8M
Free Cash Flow$28.3M
Industry P/E40.9

Technical Analysis

TrendBearish
RSI54.7
Support$3.41
Resistance$4.21
MA 20$3.80
MA 50$3.91
MA 200$6.81
MACDBullish
VolumeDecreasing
Fear & Greed Index92.95

Valuation

Fair Value$3.47
Target Price$7.50
Upside/Downside90.48%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.92
Volatility47.03%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.